SLDB Stock Forecast: Solid Biosciences, Inc. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Solid Biosciences, Inc. hold a median 12-month price target of $19 — +196.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Solid Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (72): The shares have been drifting up relative to others.
Quality (31): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SLDB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SLDB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +196.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | William Blair | Assumes | Outperform | — |
| 15 Oct 2026 | UBS | Initiates | Buy | $20 |
| 16 Sept 2026 | RBC Capital | Initiates | Outperform | $18 |
| 14 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 27 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $16 → $26 |
| 21 Aug 2026 | Truist Securities | Maintains | Buy | $16 → $20 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $25 |
| 18 May 2026 | Wedbush | Reiterates | Outperform | — |
| 13 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2026 | Wedbush | Maintains | Outperform | — |
| 25 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 20 Mar 2026 | Needham | Reiterates | Buy | — |
| 12 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 11 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Feb 2026 | Needham | Reiterates | Buy | — |
| 14 Jan 2026 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SLDB.
This page is one stock. Monday covers all of them.
SLDB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SLDB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Solid Biosciences, Inc. returned +40.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SLDB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.0×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −76.9%
- Return on assets
- −41.8%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solid Biosciences, Inc. has a market value of $697.6M and an enterprise value of $368.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$207.1M.
Free cash flow in the twelve months to 30 June 2026: −$187.8M.
Solid Biosciences, Inc. spent $13.6M on share buybacks in the twelve months to 30 June 2026.
Solid Biosciences, Inc. employs 121 people.
Data provided by Twelve Data
SLDB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SLDB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Solid Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SLDB
What is the SLDB stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Solid Biosciences, Inc. have a median 12-month price target of $19, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SLDB stock a buy right now?
Of the 15 analysts covering Solid Biosciences, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Solid Biosciences, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SLDB?
As at 21 Nov 2026, Solid Biosciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).
Will SLDB stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +196.0% from the last close, and Ticker Nerd's factor model ranks Solid Biosciences, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SLDB stock forecast for 2030?
No analyst covering Solid Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLDB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.
How has SLDB stock performed over the past year?
Solid Biosciences, Inc. returned +40.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Solid Biosciences, Inc. do?
Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy.
About Solid Biosciences, Inc.
Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy. Its work centers on addressing severe genetic disorders through targeted therapies designed to act on the underlying disease biology rather than on symptoms alone. The company serves the biotechnology and rare-disease markets, where its research and clinical development efforts are aimed at conditions with significant unmet medical need. Headquartered in Charlestown, Massachusetts, Solid Biosciences Inc. operates as a life sciences company with a focus on translating genetic science into treatments for patients with serious inherited diseases.
CEO Mr. Alexander G. Cumbo · 121 employees · United States · https://www.solidbio.com